Tango Therapeutics (TNGX) Other Non Operating Income (2020 - 2026)

Tango Therapeutics' Other Non Operating Income history runs 7 years deep, the most recent figure standing at $1.1 million for Q1 2026.

• In Q1 2026, Other Non Operating Income changed 0.47% year-over-year to $1.1 million; the TTM figure through Mar 2026 stood at $4.1 million (down 37.33% YoY), while the FY2025 annual figure was $4.1 million, down 46.54% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $1.1 million, down from $1.4 million in the prior quarter.
• The five-year high for Other Non Operating Income was $2.2 million in Q1 2024, with the low at -$47000.0 in Q1 2022.
• The 5-year median for Other Non Operating Income is $1.2 million (2023), against an average of $1.2 million.
• The sharpest annual moves came in 2023 and 2025: Other Non Operating Income soared 2689.36% in 2023, then tumbled 63.96% in 2025.
• Tango Therapeutics' Other Non Operating Income stood at $967000.0 in 2022, then soared by 113.13% to $2.1 million in 2023, then fell by 28.38% to $1.5 million in 2024, then decreased by 6.5% to $1.4 million in 2025, then slipped by 21.81% to $1.1 million in 2026.
• Business Quant data shows TNGX's Other Non Operating Income at $1.1 million in Q1 2026, $1.4 million in Q4 2025, and $705000.0 in Q3 2025.